S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
S&P 500   3,966.30 (+0.82%)
DOW   33,845.61 (+0.74%)
QQQ   284.25 (+1.33%)
AAPL   143.32 (+1.69%)
MSFT   246.56 (+0.90%)
META   115.70 (+1.55%)
GOOGL   94.11 (-0.87%)
AMZN   90.70 (+2.53%)
TSLA   174.71 (+0.38%)
NVDA   167.58 (+3.96%)
NIO   13.41 (+6.60%)
BABA   93.29 (+5.62%)
AMD   70.96 (+1.17%)
T   19.27 (-0.16%)
MU   55.50 (+3.12%)
CGC   3.23 (-0.31%)
F   13.17 (+0.53%)
GE   85.12 (+0.14%)
DIS   93.01 (+0.93%)
AMC   6.41 (+5.95%)
PYPL   75.74 (+1.77%)
PFE   50.51 (+0.54%)
NFLX   311.81 (+1.10%)
NASDAQ:MASI

Masimo - MASI Price Target & Analyst Ratings

$141.30
+1.91 (+1.37%)
(As of 12/8/2022 10:33 AM ET)
Add
Compare
Today's Range
$138.69
$141.51
50-Day Range
$110.88
$146.93
52-Week Range
$108.89
$299.78
Volume
977 shs
Average Volume
643,701 shs
Market Capitalization
$7.43 billion
P/E Ratio
46.79
Dividend Yield
N/A
Price Target
$189.43

Masimo Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$189.43
34.06% Upside
High Prediction$295.00
Average Prediction$189.43
Low Prediction$135.00
TypeCurrent
12/8/21 to 12/8/22
1 Month Ago
11/8/21 to 11/8/22
3 Months Ago
9/9/21 to 9/9/22
1 Year Ago
12/8/20 to 12/8/21
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$189.43$192.43$183.80$308.33
Predicted Upside34.06% Upside20.99% Upside12.05% Upside16.72% Upside
Get Masimo Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for MASI and its competitors with MarketBeat's FREE daily newsletter.


MASI Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

MASI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Masimo Stock vs. The Competition

TypeMasimoMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.66
2.48
Consensus RatingModerate BuyBuyHold
Predicted Upside35.90% Upside595.34% Upside15.57% Upside
News Sentiment RatingPositive News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
442
66.67%
Underperform Votes
221
33.33%
Avg. Outperform Votes
164
66.40%
Avg. Underperform Votes
83
33.60%
Avg. Outperform Votes
853
68.13%
Avg. Underperform Votes
399
31.87%

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/5/2022Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$149.00 ➝ $173.00+18.90%
11/9/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetNeutral$150.00 ➝ $135.00+9.69%
10/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$180.00+38.86%
9/15/2022Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradePeer Perform ➝ Outperform$165.00+9.51%
9/13/2022Loop Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$206.00+40.73%
9/12/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$162.00 ➝ $172.00+10.08%
2/16/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$325.00 ➝ $295.00+28.91%
10/12/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform
4/29/2021Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$310.00+33.37%
7/9/2020BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingHold
12/17/2019Piper Jaffray Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight$161.00 ➝ $175.00+11.42%
(Data available from 12/8/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












MASI Price Target - Frequently Asked Questions

What is Masimo's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Masimo stock is Moderate Buy based on the current 1 hold rating and 6 buy ratings for MASI. The average twelve-month price prediction for Masimo is $189.43 with a high price target of $295.00 and a low price target of $135.00. Learn more on MASI's analyst rating history.

Do Wall Street analysts like Masimo more than its competitors?

Analysts like Masimo more than other Medical companies. The consensus rating for Masimo is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how MASI compares to other companies.

Do MarketBeat users like Masimo more than its competitors?

MarketBeat users like Masimo more than other Medical companies. 66.67% of MarketBeat users gave Masimo an outperform vote while medical companies recieve an average of 66.26% outperform votes by MarketBeat users.

Is Masimo being upgraded by Wall Street analysts?

Over the previous 90 days, Masimo's stock had 1 upgrade by analysts.

Does Masimo's stock price have much upside?

According to analysts, Masimo's stock has a predicted upside of 22.74% based on their 12-month price targets.

What analysts cover Masimo?

Stock Ratings Reports and Tools

This page (NASDAQ:MASI) was last updated on 12/8/2022 by MarketBeat.com Staff